Male Breast Cancer Market Size was valued at USD 1.43 Billion in 2023. The Global Male Breast Cancer industry is projected to grow from USD 1.82 Billion in 2024 to USD 4.03 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.27% during the forecast period (2024 - 2032).
Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.
Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.
Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.
The male breast cancer market has been segmented into type, cancer diagnosis, and treatment.
The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.
By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are further segment into, surgery and radiation therapy.
Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.
Hormone therapy is further segmented into, using drugs and orchiectomy (castration).
Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.
Some of the key players in the male breast cancer market are:
Geographically, the Americas is anticipated to dominate the male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833.
Europe is expected to hold the second largest position in the male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.
Male Breast Cancer Market, by Type
Male Breast Cancer Market, by Diagnosis
Male Breast Cancer Market, by Treatment
BY Treatment
Male Breast Cancer Market, by Region
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 4.03 Billion by 2032 |
| CAGR | 4.27% (2024-2032) |
| Base Year | Â Â 2023 |
| Forecast Period | Â Â 2024 - 2032 |
| Historical Data | Â Â 2022 |
| Forecast Units | Â Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, end user, Region |
| Geographies Covered | America, Europe, Asia Pacific, Middle East and Africa |
| Key Vendors | Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG |
Male Breast Cancer Market Highlights:
Frequently Asked Questions (FAQ) :
The Americas is expected to lead the Male Breast Cancer Market.
The Male Breast Cancer Market is projected to grow at a 4.27% CAGR between 2024-2032.
Rising obese population and favorable healthcare expenditure are boosting market growth.
High treatment cost may limit market growth.
Different strategies used by industry players to create a dominance in the Male Breast Cancer Market include strategic alliances, collaborations, expansions, and product launches.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
